Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Racemorphan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 9/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 9/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 8/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 8/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 8/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 8/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 8/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 5/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | SCN1A | P35498 | 2/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 2/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levorphanol SCHEMBL5171217 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL24335 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL14326930 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL16310821 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL3495833 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL21095576 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL12232844 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL22791693 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL22722062 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Dextrorphan SCHEMBL20535964 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 798 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228771-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-07-17 | — | — | US | claimed |
| EP-4565202-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-06-11 | — | — | EP | claimed |
| US-20250032479-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS INC (US) | 2025-01-30 | — | — | US | claimed |
| US-12076316-B2 | Levorphanol prodrugs and processes for making and using them | ZEVRA THERAPEUTICS INC. | 2024-09-03 | — | — | US | claimed |
| WO-2023187225-A1 | ALKALINE INTRAORAL PRODUCTS | AMPLICON AB (SE) | 2023-10-05 | — | — | WO | claimed |
| EP-4247340-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | Bexson Biomedical, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| US-11534454-B2 | Complexing agent salt formulations of pharmaceutical compounds | BEXSON BIOMEDICAL, INC. (US) | 2022-12-27 | — | — | US | claimed |
| WO-2022109050-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| US-20220152088-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL, INC. | 2022-05-19 | — | — | US | claimed |
| US-20220096463-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2022-03-31 | — | — | US | claimed |
| WO-2004043460-A1 | SYNERGISTIC COMBINATIONS WITH ANALGESIC PROPERTIES COMPRISING N-ACYLATED 4-HYDROXYPHENYLAMINE DERIVATIVES | LSU MEDICAL CENTER FOUNDATION (US) | 2004-05-27 | — | — | WO | claimed |
| US-20040092541-A1 | SYNERGISTIC COMBINATIONS INCLUDING N-ACYLATED 4-HYDROYPHENYLAMINE DERIVATIVES | NATIONAL SCIENCE FOUNDATION | 2004-05-13 | — | — | US | claimed |
| US-20040052731-A1 | Abuse-deterrent pharmaceutical compositions of opiods and other drugs | COLLEGIUM PHARMACEUTICALS, INC. | 2004-03-18 | — | — | US | claimed |
| US-20030032001-A1 | Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors, and brain and spinal cord injuries using microelectrodes with microvoltammetry | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK, THE | 2003-02-13 | — | — | US | claimed |
| EP-0608893-B1 | Compositions for inhibiting the development of tolerance to and/or dependence on an additive substance | UNIV VIRGINIA COMMONWEALTH (US) | 2001-12-12 | — | — | EP | claimed |
| US-5654281-A | Inhibiting the development of tolerance to and/or dependence on an addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1997-08-05 | — | — | US | claimed |
| US-5556838-A | BLOCKING N-METHYLASPARTATE RECEPTORS TO PREVENT ADDICTION | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1996-09-17 | — | — | US | claimed |
| EP-0608893-A1 | Inhibiting the development of tolerance to and/or dependence on an additive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-08-03 | — | — | EP | claimed |
| US-5321012-A | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL COLLEGE (US) | 1994-06-14 | — | — | US | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032479-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885GRIN1 1752/4885GRIN2A 1875/4885 |
| US-12076316-B2 | Levorphanol prodrugs and processes for making and using them | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885GRIN1 1734/4885GRIN2A 1836/4885 |
| US-20040092541-A1 | SYNERGISTIC COMBINATIONS INCLUDING N-ACYLATED 4-HYDROYPHENYLAMINE DERIVATIVES | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885GRIN1 301/4885GRIN2A 428/4885 |
| US-20220152088-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SLC10A1, SLC5A6, MC2R | OPRM1 3832/4885GRIN1 750/4885GRIN2A 1325/4885 |
| US-11534454-B2 | Complexing agent salt formulations of pharmaceutical compounds | SLC10A1, SLC5A6, MC2R | OPRM1 3832/4885GRIN1 750/4885GRIN2A 1325/4885 |
| US-20220096463-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885GRIN1 1734/4885GRIN2A 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.